- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
The objective of the trial is to evaluating the feasibility of dose increase by a boost of curietherapy in PDR (at least 40 Gy on D95) associated to extern radiotherapy (34 Gy) in intermediate risk in prostate cancer.
Critère d'inclusion
- Prostate Cancer With Intermediate Risk